Ausgebrochen!!!! ....................................-CLTR - 500 Beiträge pro Seite

[rainrain]

Tach,

Coulter hat den Widerstand bei 27$ überwunden und nun ist der Weg frei bis 36$..
Ich bin dabei. Ihr auch??








Research Analyst`s Earnings Estimates and Actuals

Consensus Estimate for Current Fiscal Year -3.15 per sh. Consensus Estimate for Next Fiscal Year -1.12 per sh.

Consensus Estimate for Current Quarter -0.90 per share

>>>Actual Earnings Last Quarter -0.75 per share<<<

EPS Surprise Last Quarter 17% per share


Corporate Profile for Coulter Pharmaceutical, Inc., dated Aug. 25, 2000
FRIDAY, AUGUST 25, 2000 6:05 AM
- BusinessWire

Aug 25, 2000 (BUSINESS WIRE) -- The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.

Published Date: Aug. 25, 2000

Company Name: Coulter Pharmaceutical, Inc.

Address: 600 Gateway Blvd.
South San Francisco, CA 94080-7014

Main Telephone
Number: 650/553-2000

Internet Home
Page Address
(URL): www.coulterpharm.com

Chief Executive
Officer: Michael F. Bigham

Chief Financial
Officer: William Harris

Investor Relations
Contact: Sylvia Wheeler
Business number: 650/553-2000
E-mail address: [e-mail]

Industry: Biotechnology

Trading Symbol/
Exchange: NASDAQ/CLTR

Company description: Coulter Pharmaceutical, Inc. is engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. The company currently is developing a family of therapeutics based upon two drug development programs: therapeutic antibodies and targeted oncologics. The company`s most advanced product candidate is Bexxar(TM), a monoclonal antibody conjugated to a radioisotope. The company`s therapeutic antibodies program also includes an interferon receptor antagonist. Initial efforts in the targeted oncologics program are based on tumor activated prodrug (TAP) and tumor-specific targeting (TST) technologies. For more company information, visit Coulter Pharmaceutical`s web site at http://www.coulterpharm.com.

CONTACT: Coulter Pharmaceutical, Inc.

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
PHARMACEUTICAL
PROFILE:
YES

schöne Grüße

rainrain

[epicuraul]

was für ein ausbruch!
diese umsätze! einfach überwältigend.
nachdem ja (fast) alle anderen ausbrüche zuverlässig nivelliert wurden, kann man nun getrost short gehen, zumal die 28$ eine gute unterstützung geben.

[rainrain]

nochmal genauer (auch für epicuraul)




COULTER PHARMACEUTICAL / 222116105 NAS
27,62 +1,06 +4,00%

28.08.
17.15 Uhr

[sungi]

was für ein Ausbruch ! grins lach ! was sagt dir eigentlich der RSI?
abgesehen davon schau dir ma ne CELGENE an !! das ist ein Ausbruch!

[BFBR]

Hier der "vertrauenserweckende" 5-Jahreschart:

[BFBR]

Entschuldigung. Ich meinte natürlich den 3-Jahreschart.

[rainrain]

na, was hab ich euch gesagt?
geht ab wie Rakete

rr

[toller]

hi. sehe, dass hier relativ wenige, um nicht zu sagen nur einer in coulter investiert ist. jedenfalls freut es mich genause, dass endlich was passiert. warte seit 23Euro (22.mai) daruf, dass die teile ausbrechen, so hat man mir das nämlich mal angepriesen (einer der berüchtigten "ich habe gehört, dass...dann gehen die ab wie ne rakete"-tips).

naja. viel erfolg beim traden. und vergiss nicht, früh genug rauszugehen, denn der handel in D-land ist sowas von gering wenn die teile steigen, jeder wartet auf die 50++ euro.

[rainrain]

@toller
ich werd noch länger warten, mind. noch 2 Jahre,
und dann abgrasen!

rainrain

[toller]

@rainrain

es geht weiter. warte wohl auch noch etwas länger. aber ob es 2 jahre werden, dass weiss ich nicht genau. Was macht dich bei coulter so sicher?

kennst Du Boston Biomedica (in USA symbol BBII, WKN in D 904312)? hab die seit anfang des jahres auf der watchlist. hab bei nem börsenspiel damit rein zufällig(!) mal 20.000 euro gemacht, als die auf 14€ sprangen. hab dann die kohle virtuell auch wieder schritt für schritt verloren ;-))
naja jedenfalls gingen die heute ab. in usa 50%, kurzzeitig sogar mal in BErlin 72%. leider ziemlich geringes handelsvolumen in D-land.

übrigens: wie geht das, dass bei deinem weiter oben eingeblendeten posting mit den charts (posting vom 28.08.00, die bilder mit bollinger-bands und dem RSI-Chart) auf dem chart das Datum 11.09.00 steht?

grüße

[toller]

@rainrain

...ok. ok. bin neu hier. sehe gerade, dass die charts heute schon wieder mit datum 12.09.00 sind, sprich immer aktualisiert. toll dass sowas geht.

Coulter sieht heute 33$ in USA.
sag ich mal so einfach

[rainrain]

@Toller
auf Coulter bin ich durch den "Global Biotech Investing" Börsenbrief gekommen so Anfang März, gutes Blatt. Bin zu 49€ rein mit Anlagesicht auf 2 Jahre. Wir werden bei Coulter bald die Höchststände knacken.
Die charts gibts unter http://www.bigcharts.com,
dann tippst du CLTR ein und gehst auf interactive chart, dann
kannste rumspielen...
Auch interessant ABSC (Aurora Bioscience)..

Gruß

rainrain

[claudechabrol]

ist echt ein seltener zufall-kaufte coulter kurz vor deinem posting und gestern hab ich aurora gekauft
denke bei besserer marktlage wäre absc sicher eine gute kurzfristige 50% chance
cu

[rainrain]

@claudechabrol
gut so, wir haben wohl `nen ähnlichen Geschmack

CLTR hat neues Hoch 33,3125$



Auch interessant:

Trinity Bio.
Vical Inc.


rainrain

[claudechabrol]

absc-schade bei dem chart,es scheint als wenn nicht nur ein fonds aussteigt

[toller]

hey, grund zur freude....habt ihr den kurzzeitigen Ausbruch in USA auf 38$ gesehen?? scheint echt was im busch zu sein.

Coulter wird in folgendem artikel kurz von einem Analysten erwähnt, allerdings in einem nicht so positiven Zusammenhang. bei Immunomedics ist angeblich ein Patient in Testphase III an dem verabreichten Testmed. gestorben. dabei werden auch Unternehmen wie Coulter genannt, die mit ähnlichen Verfahren testen, in dem Sinne, hier seien ebensolche Risiken auch vorhanden. Komisch dann der Ausbruch in USA, hätte erwartet, dass die Käufer bzw. Aktienbesitzer etwas skeptisch werden....

Update: Immunomedics Says Drug Trials Haven`t
Been Halted
By Dane Hamilton
Staff Reporter
9/15/00 11:43 AM ET


Immunomedics (IMMU:Nasdaq - news) denied Friday that clinical trials of an experimental cancer drug were shut down after a patient died.

"No clinical trials sponsored by Immunomedics have been halted because of adverse events or deaths," CEO David Goldenberg said in a press release. The company said it continued to enroll patients in early-stage trials of yttrium-90-LymphoCide, and that its LymphoCide pivotal trials were on schedule.

The stock rose 88 cents, or 3.9%, to $23.85 at midday.

Updated from 8:37 p.m. EDT Sept. 14:

Immunomedics Shuts Down Drug Trial After Patient Death

Immunomedics (IMMU:Nasdaq - news) was forced to shut down clinical trials of an experimental cancer drug after a patient died, according to an analyst whospoke with the company.

The drug, which employs a radioactive substance to fight cancer, was in early-stage clinical trials at the Garden State Cancer Center, according to Stefan Loren, analyst with Legg Mason Wood Walker. The trial of the drug ended in the last several weeks, although the company hasn`t publicly discussed the matter, said Loren.

Repeated phone calls for confirmation to Morris Plains, N.J.-based
Immunomedics weren`t returned. A spokesman for the Garden State Cancer
Center declined questions and referred calls to Immunomedics. David
Goldenberg, president of Garden State Cancer Center, is also chairman and chief executive of Immunomedics. Loren said he spoke with Goldenberg yesterday.

Shares in Immunomedics closed up 38 cents at $22.75 Thursday, giving it a market value of $1.1 billion. The stock, which traded for barely $1 a year ago, rose 40-fold this spring as biotech stocks took off, and has since held much of that value as investors speculate on the promise of the company`s development efforts and its attempts to find a partner.

Little to Go On

It isn`t clear whether the drug was the cause of the patient death and information about the patient hasn`t been released. Typically in questionable patient deaths, however, the Food and Drug Administration shuts down experimental drug trials while an assessment is made. Clinical trials of the drug were partly funded
by the National Cancer Institute, an NCI spokeswoman said.

Cancellation of a clinical trial program, particularly if a patient death occurs, often causes abrupt declines in the market capitalization of smaller drug companies, since those valuations are usually based on the prospects for drugs in development rather than actual sales. It can also affect the prospects for experimental classes of drugs, such as those Immunomedics is testing.

Similar cancer drugs are under development at IDEC Pharmaceuticals (IDPH:Nasdaq -news) and Coulter (CLTR:Nasdaq - news).

Immunomedics is testing a number of experimental cancer drugs both with and without radioactive substances. Its most advanced drug, LymphoCide for non-Hodgkin`s lymphoma, is entering phase three, or late-stage clinical trials. A less advanced version of the drug, which uses a radioactive substance called 90-yttrium, is in earlier-stage trials. The company is also testing another drug called Cea-side in colorectal, breast and lung cancer, both with and without
"y-90," the radioactive substance.

Radioactive?

Loren, who rates the company a strong buy, said it was one of the radioactive
drug trials that was halted, but that the $1.1 billion market value of the company
mostly rests on the value of the advanced, nonradioactive version of LymphoCide.
Legg Mason does no corporate finance work for Immunomedics, which reported a
loss of $10 million on sales of $6 million for the year ended in June.

Immunomedics has said it`s seeking a corporate partner to further develop and
market LymphoCide, a factor that could further determine the company`s ultimate
value, said Loren.

"The fundamental value of the company will be determined when they get a deal
for LymphoCide, and who it is with and how much funding they will get," said
Loren.

[rainrain]

>>>kam heute:


18.019.2000 12:51
BST Coulter and SmithKline re-submit cancer drug for U.S. approval

U.S biotech firm Coulter (us:cltr) and its marketing partner, drugs giant SmithKline Beecham (uk:sb)(us:sbh), announced on Monday they had re-submitted their application for approval of Coulter`s Bexxar cancer treatment to the U.S.`s Food and Drugs Administration (FDA). In August of 1999, Coulter shares fell sharply when the FDA refused to consider the company`s application for approval of Bexxar for certain cases of non-Hodgkin`s Lymphoma, a blood-cell cancer, insisting on changes in the way the clinical trial data were analysed and presented. Bexxar is Coulter`s key product, and if approved could potentially yield sales in the hundreds of million of dollars. SmithKline shares were up 1.2 percent at 875 pence in London midday trading. Coulter trades on the Nasdaq, and the announcement came before the start of the U.S. session.

Quelle: Bigcharts/FT MarketWatch



..die ist bald nicht mehr 2stellig

rainrain

[rainrain]

auch noch:

Coulter Pharmaceutical and SmithKline Beecham Announce the Submission of a Biologics License Application for Bexxar to FDA
MONDAY, SEPTEMBER 18, 2000 7:28 AM
- BusinessWire

SOUTH SAN FRANCISCO, Calif. & PHILADELPHIA, Sep 18, 2000 (BW HealthWire) -- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR) and SmithKline Beecham (NYSE:SBH) today announced the re-submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Bexxar(TM) (tositumomab, iodine I 131 tositumomab). The companies are seeking marketing approval of Bexxar for the treatment of patients with relapsed or refractory, low-grade or transformed low-grade B-cell non-Hodgkin`s lymphoma (NHL).

"We are pleased to have responded to all questions from the FDA that followed from our original submission," said Michael F. Bigham, president and chief executive officer of Coulter. "We look forward to continue working closely with our partner SmithKline Beecham and the FDA to make Bexxar commercially available to the many NHL patients who may benefit from the therapy."

Kevin Lokay, vice president and director of Oncology for SmithKline Beecham, said, "We are proud to be working in partnership with Coulter on such an important and novel therapy as Bexxar. As a company committed to oncology, we look forward to providing a new treatment option to patients with non-Hodgkin`s lymphoma."

Bexxar has been designated a Fast Track Product by the FDA because one of the targeted indications for the therapy is transformed, low-grade non-Hodgkin`s lymphoma, a life-threatening disease representing an unmet medical need. Because Bexxar is designated as a fast track product, the companies will request a Priority Review.

Bexxar is a radioimmunotherapy involving an antibody conjugated to iodine 131 (I-131) that attaches to a protein found only on the surface of B-cells, including non-Hodgkin`s lymphoma B-cells. The properties of the I-131 radioisotope allow an appropriate patient-specific dose to be easily determined and administered. Bexxar is believed to work through multiple mechanisms of action resulting from immune system activity of the monoclonal antibody and the therapeutic effects of the I-131 radioisotope. Through the targeted approach of Bexxar, the tumor cells receive a greater concentration of the therapeutic radiation whereas the radiation to normal tissues is minimized.

Non-Hodgkin`s lymphoma is a form of cancer that affects the blood and lymphatic tissues. NHL currently is the sixth leading cause of death among cancers in the United States and has the second fastest growing mortality rate. According to statistics from the National Cancer Institute, approximately 300,000 people are afflicted with NHL in the United States alone. It is estimated that approximately 140,000 people have low-grade or transformed low-grade disease, and 120,000 people have intermediate-grade disease.

Coulter Pharmaceutical, Inc. is engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. The company currently is developing a family of therapeutics based upon two drug development programs: therapeutic antibodies and targeted oncologics. The company`s most advanced product candidate is Bexxar(TM), a monoclonal antibody conjugated to a radioisotope. The company`s therapeutic antibodies program also includes an interferon receptor antagonist. Initial efforts in the targeted oncologics program are based on tumor activated prodrug (TAP) and tumor-specific targeting (TST) technologies. For more company information, visit Coulter Pharmaceutical`s web site at http://www.coulterpharm.com.

SmithKline Beecham -- one of the world`s leading healthcare companies -- discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products. For company information, visit SmithKline Beecham on the World Wide Web at http://www.sb.com.

SmithKline Beecham Oncology is committed to the research, development, manufacturing and marketing of therapeutic and supportive care products in oncology. Currently, SB Oncology markets Hycamtin(R) (topotecan hydrochloride), Kytril(R) (granisetron hydrochloride) and Compazine(R) (prochlorperazine), and has novel agents in development.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements for Coulter Pharmaceutical, Inc. that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of Bexxar(TM) or the company`s other product candidates and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC). In particular, see "Risk Factors" in the company`s Registration Statement on Form S-3 filed Aug. 30, 2000, and Annual Report on Form 10-K for the year ended Dec. 31, 1999.

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, SmithKline Beecham cautions investors that any forward-looking statements or projections made by the company, including those made in this news release, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the company`s operations are discussed in Exhibit 99 to the company`s Annual Report on Form 20-F for 1999, filed with the U.S. Securities and Exchange Commission.

CONTACT: Coulter Pharmaceutical, Inc.
Sylvia Wheeler, 650/553-1887
or
SmithKline Beecham
Jennifer Armstrong, 215/751-5664
Tom Curry, 215/751-5419
or
Abby Hayes, 212/598-2827

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

KEYWORD: CALIFORNIA PENNSYLVANIA
INDUSTRY KEYWORD: PHARMACEUTICAL
BIOTECHNOLOGY
MEDICAL
PRODUCT



News Provided By COMTEX


rainrain

[toller]

Thursday September 21, 7:57 am Eastern Time
Press Release
Coulter Pharmaceutical Acquires Rights to Potent Anti-Cancer Compounds


SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Sept. 21, 2000-- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR - news) today announced that it has acquired rights to a class of ultra-potent anti-cancer compounds from Kyowa Hakko Kogyo Co., Ltd. of Japan. Coulter intends to enhance the potency of these agents by incorporating them into Coulter`s proprietary tumor activated prodrug (TAP) and tumor specific targeting (TST) technologies. The resulting drug candidates will be designed to target the potent anti-cancer power of these agents directly to tumor cells to maximize efficacy while minimizing side-effects to normal tissues.

The ultra-potent compounds, Duocarmycin B2 and KW-2189, have been shown to be 1,000 times more potent than standard chemotherapy drugs and work by directly attacking the DNA of cancer cells, causing cell death. They represent a new class of chemotherapeutics which may be added to the armamentarium available to oncologists. Drug candidates using these compounds have already been created by Coulter and have shown significant activity against multi-drug resistant human tumor cell lines. The company is currently conducting studies to support human clinical trials.

``We are pleased to enter into this agreement with Kyowa Hakko Kogyo, the discoverer of the Duocarmycin class of ultra-potent compounds and a leader in their development,`` said Michael F. Bigham, president and chief executive officer of Coulter. ``These newly acquired compounds are extremely potent anti-cancer agents which can be delivered directly to tumors using our proprietary tumor targeting technologies.``

Under the terms of the agreement, Coulter acquired exclusive worldwide rights to all uses of the ultra-potent agents. Detailed financial terms of the agreement were not disclosed but include an upfront payment to Kyowa Hakko Kogyo with future payments committed for certain development milestones and royalties upon commercialization.

Coulter is developing its tumor activated prodrug (TAP) technology to enhance the specificity of chemotherapeutic agents for tumor cells. TAP prodrugs are designed to remain stable in circulation until being activated preferentially at the tumor site. As a result, relatively larger quantities of cytotoxic agents are expected to reach and enter malignant cells compared to normal cells. This approach is designed to permit an increase in maximum tolerated dosages, potentially overcoming drug resistance in some cancer cells. In addition to TAP, the company is also developing tumor specific targeting (TST) technologies including peptides, non-peptides and internalizing antibodies. These targeting approaches are designed to bind the TST compound selectively to tumor target cells. Upon binding, the TST compound is internalized into the cell and the ultra potent payload is released from the targeting entity. Once released, the ultra potent drug acts on its intracellular target and kills the tumor cell.

Coulter Pharmaceutical, Inc. is engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. The company currently is developing a family of therapeutics based upon two drug development programs: therapeutic antibodies and targeted oncologics. The company`s most advanced product candidate is Bexxar(TM), a monoclonal antibody conjugated to a radioisotope. The company`s therapeutic antibodies program also includes an interferon receptor antagonist. Initial efforts in the targeted oncologics program are based on tumor activated prodrug (TAP) and tumor-specific targeting (TST) technologies. For more company information, visit Coulter Pharmaceutical`s web site at http://www.coulterpharm.com.

[rainrain]

hört sich genial an, ich find keinen Haken,
nur der Kurs zögert noch..
hmmm..

abwarten

rainrain

[toller]

noch ne news:

Monday October 2, 8:32 am Eastern Time
Press Release
Coulter Pharmaceutical Acquires Rights to Novel Technology Related to Rheumatoid Arthritis Treatment
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Oct. 2, 2000-- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR - news) today announced that it has entered into a license and research agreement with Yissum, the technology transfer company of Hebrew University, for technology, know-how and worldwide intellectual property rights relating to a novel approach to treating rheumatoid arthritis (RA).

This new approach involves reducing RA joint inflammation by targeting the synovial cells responsible for infiltrating and inflaming joints. Scientists led by Professor David Naor at Hebrew University discovered a novel variant of the CD44 cell surface marker located on synovial cells implicated in the disease process. With this marker now identified, scientists can develop monoclonal antibodies which will target the variant CD44 marker on these synovial cells. Under the research agreement, Coulter Pharmaceutical and Hebrew University are collaborating on the research and development of monoclonal antibodies against the CD44 variant.

``We are pleased to enter into this agreement with Hebrew University,`` said Michael F. Bigham, president and chief executive officer of Coulter. ``We believe their discovery of this new cell surface marker on synovial cells will lead to exciting new developments in the treatment of rheumatoid arthritis. Our goal is to offer therapeutic alternatives which will address the pain and suffering of the many patients with this debilitating disease.``

Under the terms of the agreement, Coulter acquired exclusive worldwide rights to the variant CD44 invention of Hebrew University. Additionally, Coulter will become the license holder of all technology and products developed under the collaborative research effort between Coulter and Hebrew University. In return, Coulter has committed an undisclosed two year research grant as well as milestones and royalties associated with product developments.

Rhueumatoid Arthritis, one of the most common forms of arthritis, is an autoimmune disease affecting approximately 2.1 Americans, mostly women, between the ages of 20 and 50. It is a chronic inflammatory condition damaging cartilage and bone within the joints and may also affect internal organs.

[rainrain]

Coulter Pharmaceutical and Cobra Therapeutics Collaborate On Gene Expression Technology
TUESDAY, OCTOBER 03, 2000 8:13 AM
- BusinessWire

SOUTH SAN FRANCISCO, Calif., Oct 3, 2000 (BW HealthWire) -- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR) and Cobra Therapeutics Ltd, the gene therapy subsidiary of ML Laboratories, today announced that the companies have entered into a collaboration to jointly develop and commercialize Cobra`s platform gene expression technology.

The technology, known as Ubiquitous Chromatin Opening Elements (UCOEs), is a new class of gene expression elements which induce efficient productivity from genes introduced into target cells. UCOE transfected cells yield more predictable, high-level expression of gene products in a sustained fashion. UCOEs have a wide range of potential applications including gene therapy, functional genomics and the manufacture of therapeutic proteins including recombinant antibodies.

"We are pleased to enter into this broad collaboration with Cobra whose UCOE technology is a perfect complement to our antibody therapeutics program," said Michael F. Bigham, president and chief executive officer of Coulter. "UCOE technology is a powerful enabling platform technology with dramatic potential in the creation and manufacture of therapeutics. We look forward to leveraging this platform in our own internal programs as well as licensing the technology to external parties."

Stuart Sim, chief executive of ML Laboratories said, "We are delighted to have Coulter partner the development of our UCOE technology for use in the production and evaluation of antibodies as their expertise in this area is considerable and complementary to our own capabilities. The application of our technology in this area is particularly important as it represents a major class of therapeutic proteins and consequently offers significant commercial potential."

Under the terms of the agreement, the two companies will jointly develop and commercialize the UCOE technology within an agreed upon plan. In return, Coulter will pay Cobra an upfront payment of (pound) 1.0 million and event-based milestone and sublicense fees. The agreement allows for exclusive, royalty-free commercialization of the first two products derived within each company`s own product line. Any products commercialized after the first two will be subject to a royalty fee. The agreement also allows for sublicensing of the technology. Coulter will principally be responsible for obtaining sublicenses in North America and Japan while Cobra will be principally responsible for all other territories. Generally, revenues from third party milestone and royalty payments will be split equally. Two pre-existing licenses established by Cobra are excluded from this agreement`s sublicense terms.

Coulter Pharmaceutical, Inc. is engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. The company currently is developing a family of therapeutics based upon two drug development programs: therapeutic antibodies and targeted oncologics. The company`s most advanced product candidate is Bexxar(TM), a monoclonal antibody conjugated to a radioisotope. The company`s therapeutic antibodies program also includes an interferon receptor antagonist. Initial efforts in the targeted oncologics program are based on tumor activated prodrug (TAP) and tumor-specific targeting (TST) technologies. For more company information, visit Coulter Pharmaceutical`s web site at http://www.coulterpharm.com.

Cobra Therapeutics is one of Europe`s leading research groups developing novel DNA technologies for applications in human gene therapy, the genomics revolution and manufacturing of biological products. In addition Cobra manufacturers DNA and viral products on a contract basis for several pharmaceutical and biotechnology companies including Glaxo Welcome at its GMP manufacturing facility in Keele, Staffs, which is one of only a small number of such facilities in Europe. Further information can be found at http://www.cobrat.com

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements for Coulter Pharmaceutical, Inc. that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of Bexxar(TM) or the company`s other product candidates and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC). In particular, see "Risk Factors" in the company`s Registration Statement on Form S-3 filed August 30, 2000, and Annual Report on Form 10-K for the year ended December 31, 1999.

CONTACT: Coulter Pharmaceutical, Inc.
Sylvia Wheeler, 650/553-2000






up, up!

RR

[toller]

hi rainrain!

war kurz davor auszusteigen am Montag, nach dem chrash von coulter in USA am Freitag (-8.x%).

bins nicht und das war gut!!! hab die news von heute auch gelesen. kommt mir so vor, als ob jeden Tag was Neues kommt. Tja, dann bleibe ich mal noch am ball. auf finance.yahoo.com kann man im Msg-Bereich ne interessante Diskussion zu coulter verfolgen. am freitag ist wohl ein Interview mit nem Top-Biotech-Analysten veröffentlicht worden, dass von der zeit vor dem Bexxar-Filing bei der FDA stammt. der hat irgendwas von "wenn bexxar überhaupt mal eingereicht wird.." erzählt und dass sie alles auf Zevalin von IDEC setzen. Das hat wohl diesen Sturz herbeigeführt. naja. abwarten.

viele gruesse und noch viel spass mit CLTR!

[rainrain]

Hi toller,
ich glaub, wir sind die einzigsten an diesem Board, die Coulter haben,
und wir werden noch mächtig Freude damit haben..
Auf jeden Fall hab ich den Eindruck, das sich bei Coulter im Moment ziemlich viel tut, was die vielen (positiven) Nachrichten zeigen.
Ich denke, das in den nächsten Monaten der Bekanntheitsgrad von Coulter in USA sowie hierzulande stark gesteigert wird..

schon schön im ++++++ heute: 33 3/4 $ +7,36%

Gruß
RR

[toller]

hier ist noch ne ältere nachricht, die, wie ich meine, schöne Aussichten birgt...irgendwohin sollen die 35Mill$, die cltr sich vorwiegend von institutionellen investoren holte (so der text) ja fließen. das heißt für mich, da werden noch ein paar news folgen....

Monday August 14, 8:30 am Eastern Time
Press Release
Coulter Pharmaceutical Announces $35.8 Million Private Placement
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Aug. 14, 2000-- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR - news) today announced that it has entered into definitive purchase agreements for the sale of 1,655,000 shares of newly issued common stock to selected institutional and other accredited investors for approximately $35.8 million. The purchase price was $21.625 per share. The shares of common stock have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration. Pacific Growth Equities, Inc. served as the placement agent for this transaction.

The Company intends to use net proceeds from this private placement to fund its commercialization efforts as well as its research and development activities including additions to personnel, pre-clinical studies, clinical trials, and manufacturing

[toller]

yes yes yes. jetzt gehts los.

Cancer Drug Bexxar Gets Priority Status

SOUTH SAN FRANCISCO, Calif. (Reuters) - Drugmakers Coulter Pharmaceutical Inc. (NasdaqNM:CLTR - news) and SmithKline Beecham Plc (NYSE:SBH - news) said on Thursday that U.S. regulators have assigned a priority review for their cancer drug Bexxar.

The companies are seeking marketing approval for their treatment of low-grade B-cell non-Hodgkin`s lymphoma, a form of cancer that affects the blood and lymphatic tissues. They said the U.S. Food and Drug Administration (news - web sites) will review the drug`s license application.

With the priority review, the agency could take action within six months from the date of submission. If approved, Bexxar could be the first approved radioimmunotherapy to become commercially available.

``The commitment by the FDA for an expeditious review of our license application moves us one important step closer to providing this novel therapy to patients,`` Michael Bigham, president and chief executive officer of Coulter, said in a release.

Last month, Coulter and SmithKline submitted a Biologics License Application to the FDA for Bexxar. The therapy has been designated a Fast-Track product because one of the targeted indications for the therapy is transformed, low-grade non-Hodgkin`s lymphoma, a life-threatening disease, the companies said. The FDA is expected to determine acceptability of the license application within 60 days of the submission

[rainrain]

wow,hört sich verdammt gut an,
wär der Hammer wenn Bexxar auf den Markt kommen würde.

Hat jemand `ne Ahnung, was die "radioimmunotherapy " genau sein soll,
konnte keine näheren Infos finden.

Danke

RR

@toller

darauf geh ich einen

[rainrain]

..aber nich kotzen, passiert mir nich!

[rainrain]

@toller und alle dies interessiert
wow..
die Übernahmephantasie läßt den Wert explodieren!

Corixa to buy Coulter for over $900 mln in stock
MONDAY, OCTOBER 16, 2000 8:26 AM
- Reuters

NEW YORK, Oct 16 (Reuters) - Biotechnology company Corixa Corp. (NASDAQ NM:CRXA) said Monday it agreed to buy Coulter Pharmaceutical Inc. (NASDAQ NM:CLTR), a maker of prospective cancer treatment Bexxar, for more than $900 million in stock.

The purchase price is based on a fixed exchange ratio of 1.003 shares of Corixa common stock for each share of South San Francisco-based Coulter common stock outstanding at the time of closing. Corixa shares closed at $44-3/16 on Friday, while Coulter closed at $30-15/16.

Corixa`s antigen discovery and immunotherapeutic product development expertise is expected to combine with Coulter`s therapeutic antibodies and targeted oncologics platforms to develop therapies for the treatment or prevention of autoimmune diseases, cancer and infectious diseases, the companies said.

Steven Gillis would remain as chairman and chief executive officer of the combined company, which wouldcontinue to operate as Corixa. Michael Bigham, current president and chief executive officer of Coulter, would join Corixa`s board of directors as vice chairman.

Rtr 08:26 10-16-00

Selector Code: reuco

Copyright 2000, Reuters News Service


die gehn noch ab!
der Ausschlag heute Mittag war erst der Anfang!

RR

[toller]

hi rainrain!

hab um 14:00 gedacht ich hätte mich verlesen, bei dem kurs in berlin. plötzlich +25%

schade ist nur, dass hier keine übernahmefantasien mehr sind, denn das ding scheint so gut wie gegessen zu sein. der preis ist festgelegt, ebenso wie die exchange ratio (closing-price am freitag).

ich bin mir nicht sicher, ob ich halten soll. der chef von corixa war co-founder von immunex und bill gates ist mit 10% an corixa beteiligt. hört sich gut an.

grüße + daumen drücken.
toller

[rainrain]

@toller
warum bist du nicht sicher, ob du sie halten sollst?
ich denke, die fantasien werden sich in nächster zeit erst,
ausbilden, da sich sowohl für coulter und corixa neue perspektiven (und riesiken?)ergeben.
Jedoch bin ich optimistisch, erstens wegen der Reaktion der Amis (Kurs geht ab), wie auch (aus folgender Analyse entnommen) dem "strong buy" rating von Thomas Dietz und die gefüllte Pipeline beider Unternehmen (16 programs in clinical development, 22 pre-clinical programs and 16 corporate partnerships concentrating ).
Also ich werde erstmal abwarten und die Entwicklung und kommende News ganz genau beäugen!

Freuen wir uns, solange der Kurs steigt

_____________________________________________________________________________________________________

Corixa to Buy Coulter
By Jamie Paton
TheStreet.com/NYTimes.com Staff reporter
10/16/00 12:24 PM ET



Corixa (CRXA:Nasdaq - news) announced Monday that it would acquire Coulter Pharmaceutical (CLTR:Nasdaq - news) for stock valued at more than $900 million, blending the two biotechnology companies` efforts to develop therapies for treating or preventing autoimmune diseases and cancer.

After the close of the deal, expected in December, the combined company would have a portfolio that includes two key late-stage clinical products: Bexxar, Coulter`s prospective therapy for use in treating non-Hodgkin`s lymphoma, and Melacine, Corixa`s melanoma vaccine.



Corixa certainly has its eyes on Bexxar, which has "potential for significant near-term revenue," Steven Gillis, chairman and chief executive of Corixa, said in a statement. Gillis will lead the combined company, which will operate under the Corixa name.

The deal will enable Corixa to take advantage of Coulter`s strong sales force and "a late-stage development team to move the company forward," said Thomas Dietz, who follows the companies for Pacific Growth Equities and rates both companies` stocks a strong buy.

Yet after Coulter and its partner, the pharmaceutical giant SmithKline Beecham, sent their application for Bexxar to the Food and Drug Administration in the summer of 1999, the government body requested that the companies resubmit their clinical trial data.

Coulter eventually sent a new application last month seeking commercial approval for Bexxar, which was given "priority review status" by the FDA. Coulter now hopes to win FDA approval within six months.

"There are certainly investors who are skeptical because of the Bexxar situation, but we feel comfortable with it," said Dietz, whose company has done underwriting for both sides, including Coulter`s initial public offering in 1997.

Seattle-based Corixa said it would exchange 1.003 shares of its stock for each Coulter share at the time of the closing. Based on Coulter`s closing price Friday of $30.94, the deal represented a 43% premium for shareholders of South San Francisco-based Coulter. The directors and executive officers of Coulter, according to the company, collectively own more than 18% of the company`s stock.

The premium for Coulter`s shares narrowed, however, after the deal was announced Monday. Shares of Corixa were trading down $7.88, or 18%, at $36.31 around midday, while Coulter`s stock was up $2.81, or 9%, at $33.75.

The Corixa and Coulter combination also would have 16 programs in clinical development, 22 pre-clinical programs and 16 corporate partnerships concentrating on autoimmune diseases, cancer and infectious diseases.

Michael Bigham, current president and chief executive of Coulter, would join Corixa`s board as vice chairman. The companies said additional announcements regarding management and board positions would be made in coming weeks.

Schöne Grüße

RR

[toller]

hihi,

werd auch mal abwarten. wenn die pipline jetzt voller als die von Immunex ist (23Mrd$ MrktKap.) dann kann da ja noch was kommen...

viele gruesse
toller

[rainrain]

ma gucken, ob es heut weiter geht..

[rainrain]

hmmm... netter Kurssprung (von ca. 32 1/2$ auf 34 5/8$) am Ende, soll mir Recht sein, auch historisch betrachtet ist die Marke von 35$ eine wichtige Linie, sollte sie in den nächsten Tagen überwunden werden, ist der Weg zu alten Höhen frei, die Indikatoren haben jedenfalls nach oben gedreht, sollte den Schwung nach oben nutzen..



RR

[rainrain]

der Freitagsschlußkurs von 35,31$ ist ein wichtiges Zeichen,
wenn es sich nicht um ein False Break wie am 15.9.00 handelt.
Das werden die nächsten Tage zeigen. Sollte sich der Kurs oberhalb der 35$ Marke halten, ist der Weg bis zu ca. 43$ frei.

* good luck *

RR

[rainrain]

Tach Leute,
hallo mein Freund toller,

Coulter Pharma macht einfach Freude!
bei dem Umfeld (IXBT -4,4%!) steigt Coulter momentan 2,45% auf 36 9/16$ und setzt seinen Aufwärtstrend konsequent durch. Um die 36-37€ hat sich in den letzten Tagen eine starke Widerstandslinie gebildet, die gerade im Begriff ist zu fallen. Sollten wir heute Abend Schlußkurse von deulich über 36$ sehen, ist der Weg zu den alten Highs frei. Eine Erfolgsgeschichte bahnt sich da an, der Krebsforschung wird immer mehr Bedeutung beigemessen!

*up, up!

RR

[rainrain]

Tach Leute,
hallo mein Freund toller,

Coulter Pharma macht einfach Freude!
bei dem Umfeld (IXBT -4,4%!) steigt Coulter momentan 2,45% auf 36 9/16$ und setzt seinen Aufwärtstrend konsequent durch. Um die 36-37€ hat sich in den letzten Tagen eine starke Widerstandslinie gebildet, die gerade im Begriff ist zu fallen. Sollten wir heute Abend Schlußkurse von deulich über 36$ sehen, ist der Weg zu den alten Highs frei. Eine Erfolgsgeschichte bahnt sich da an, der Krebsforschung wird immer mehr Bedeutung beigemessen!

*up, up!

RR

[rainrain]

nur 14 Leute gelesen???
das kann doch nicht sein, das Coulter hier kein Schwein interessiert?!
Könnt ihr nur über Vertex, Sequenom und Antisoma diskutieren?
Ich dachte hier wird einigermaßen zusammen diskutiert, und gerade im Bereich Biotech sollte keinem Unternehmen zu wenig Beachtung geschenkt werden, denn wie die Vergangenheit uns zeigt ist so manch eine Aktie für Überraschungen gut. Also ich halte Coulter für sehr interessant, und der Kursverlauf bestätigt es mir... oder liegt es an meinem thread?

Ich verstehs nicht, is mir auch wurscht...

schönen Abend noch

rainrain

[rainrain]

*in über 3h nur 25 mal gelesen

Coulter weiter auf dem Weg zum ATH
+4% bei 37 1/8 $

..schade, das sich niemand mit mir freuen will

RR

[rainrain]

....der gestrige Schlußkurs war der Grundstein zum weiteren Kursanstieg, der Ausbruch ist perfekt.
Aktuell 39 7/16 $ oder +5,87%

..es geht noch weiter!

schöne Grüße

rainrain

[toller]

Hi rainrain!!!

sorry, hab in letzter zeit einfach nicht mehr beim coulter-thread vorbei geschaut. coulter macht echt freude. ich denke ich werd mal noch ein wenig dabeibleiben;-))))))

hab mich in letzter zeit mehr um Plambeck gekümmert, liefen auch ganz gut. hatte umweltkontor seit zeichnung und bei 54 in Plambeck und winter umgeschichtet, wobei winter AG sofort ins minus (hatte tageshoch von 17 erwischt bei erstnotiz). jetzt gehts wieder, hatte auch bei 14.6 nochmal nachgefasst.

naja. schade dass ich bei coulter damals nicht mehr mut hatte auf diesen ominösen Tip zu hören. wie schonmal geschrieben, hab 50stck.

bin wirklich sehr gespannt, was die FDA zu BExxar sagt, und welche auswirkungen das auf den Kurs haben wird, denn noch ist ja wohl nicht klar, wann der Umtausch Coulter - Corixa stattfinden soll, oder?

jedenfalls toll, dass du hier die Fahne hochgehalten hast!!!
ich hatte coulter schonmal einigen leuten im Instock board empfohlen, damals waren die gerade von 19 wieder auf 22 angesrpungen (ende mai glaube ich), aber hat da auch keinen interessiert. naja Amgen immunex und celera und so waren da wohl immer interessanter.

also bis denn

(wie du immer schreibst: up up up) ;-))

[rainrain]

@toller
schön zu hören, das ich nicht der einzige mit Coulter im Depot bin, und das sich noch jemand aktiv in diesem thread herumtreibt
Freut mich auch, das du noch dabei bist...

CLTR Bid/Ask 39,625$ / 40,4375$
Kurs um 19:00 Uhr 39,75$ +6,71%

***jippiiiiieeee

meine Alexion dümpel seit Tagen seitwärts, aber ich bin optimistisch,
der Markt ist im Begriff bald wieder die Nordrichtung einzuschlagen, und dann wird ALXN `s ATH Geschichte sein...

wünsch dir noch gute Trades

was ist deine Prognose für CLTR bis Ende des Jahres?

RR

[rainrain]

..und es geht weiter aufwärts:


aktuell 40,5$




RR

[rainrain]

41,5625$ !!
>> nach oben hin offen, schaut euch das mal an


*JIPPIIEEEEHH

RR

[rainrain]

wow, schon 42,75$

ist dieser dailychart nicht ein Traum?



schönen Abend noch

rainrain

[toller]

wow. ick bin ja echt überrascht. ein Traum von Tagesgang.

bin gestern gegen 16:00 aus büro abgehauen in Besprechung und anschließend zahnschmerzmäßig nach hause. war zu hause zu faul die lahme kiste einzuschalten. dafür heute morgen dann ne echt angenehme überaschung.

herzlichen Glückwunsch allen "coultharts" (naja, herzlichen glückwunsch an Rain rain ;-)) wir scheinen ja die einzigen zu sein, die diese perle haben.....Provokation auf die sich jemand meldet?


bis denn und heute viel spass wünsch ich Dir, rain rain!!!

[rainrain]

@toller
ja, wir sind wohl die einzigen auf unserem Boot, welches noch abheben wird! Schön das ich nicht allein bin
Zu Coulter: die 43$ scheinen einen kleinen Widerstand zu bieten,
danach ist aber das ATH bei 50 bzw. 52$ dran.
Eine kleine Konsolidierung aufgrund der Indikatoren ist möglich (RSI im überkauften Bereich, ebenso die slow stochastik, die jedoch noch nach oben gerichtet ist, der MACD steht noch auf kaufen und zeigt einen Aufwärtstrend), jedoch sollte der Kurs die 40$ nicht mehr unterschreiten...



Die Krebsaktien stehen vor einem Boom!!

Gruß an alle

RR

[rainrain]

..die Reise geht doch noch weiter,
aktuell: 43,75$ +1$

Hier nochmal ein aktuelles Firmenprofil, für alle, die sich
einem künftigen Star befassen möchten:

Management`s Discussions: 10-Q, COULTER PHARMACEUTICALS INC
THURSDAY, NOVEMBER 02, 2000 1:45 PM
- Edgar Online

Company Name: COULTER PHARMACEUTICALS INC
(SYMBOL:CLTR)

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. Actual results may differ significantly from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and in our Registration Statement on Form S-3 filed on August 30, 2000 as well as in our Annual Report on Form 10-K for the year ended December 31, 1999, filed on March 27, 2000.

OVERVIEW

We are engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. We are currently developing a family of potential therapeutics based upon two drug discovery programs; therapeutic antibodies and targeted oncologies. Within these broad drug discovery programs, we are currently concentrating on several distinct platform technologies; therapeutic antibodies consisting of both conjugated and unconjugated antibody technology, and targeted oncologics based on tumor activated pro-drug ("TAP") technology and tumor specific targeting ("TST") technology. We are also developing a portfolio of proprietary ultra potent compounds which we believe will be suitable payloads for both our TAP and TST platforms. Ultra potent compounds generally are at least 1,000 times more potent than standard chemotherapeutic agents and are active against resistant tumor cells. In October 2000, we announced our intention to merge with Corixa Corporation, a research and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system.

Our most advanced product candidate, Bexxar(TM) (tositumomab, iodine I 131 tositumomab) consists of a monoclonal antibody conjugated with a radioisotope. We intend to seek initial approval of Bexxar for the treatment of low-grade and transformed low-grade non-Hodgkin`s lymphoma ("NHL") in patients who have relapsed after, or are refractory to, chemotherapy. We intend to seek expedited Biologics License Application ("BLA") review and marketing approval for Bexxar, while simultaneously pursuing clinical trials to expand the potential use of Bexxar to other indications. Bexxar is based upon the antibody therapeutics program which originated at Coulter Corporation. In September 2000, we announced the submission of a BLA for Bexxar to the Food and Drug Administration ("FDA") and in October 2000, we announced that Bexxar had been granted Priority Review Status by the FDA. In 1995, Coulter Pharmaceutical was incorporated and acquired worldwide rights to Bexxar and related intellectual property, know-how and other assets from Coulter Corporation. In 1997, Beckman Instruments, Inc. acquired Coulter Corporation, and is now known as Beckman Coulter. In December 1998, we announced a joint collaboration agreement with SmithKline Beecham Corporation ("SB") granting SB joint marketing rights to Bexxar in the United States and exclusive commercial rights internationally, except Japan. In April 2000, we announced that we reacquired rights outside the U.S. for the development and commercialization of Bexxar effective June 30, 2000.

To date, we have devoted substantially all of our resources to research and development programs, as well as selling, general and administrative activities needed to support product development and potential product sales. No revenues have been generated from product sales, and product revenues resulting from our research and development efforts, if any, will not occur until commercial availability of such product. We have a limited history of operations and have experienced significant operating losses to date. We may continue to incur significant additional operating losses in future periods and expect cumulative losses to increase substantially due to expanded research and development efforts, preclinical studies and clinical trials and development of manufacturing, marketing and sales capabilities, if anticipated product sales revenues do not offset these costs. We expect that losses will fluctuate from quarter to quarter and that such fluctuations may be substantial. There can be no assurance that we will successfully develop, manufacture and commercialize our products or ever achieve or sustain product revenues or profitability. As of September 30, 2000, our accumulated deficit was approximately $137.2 million.

RESULTS OF OPERATIONS

*Revenues

Corporate partner revenues of $2.0 million for the nine-month period ended September 30, 2000 resulted from the recognition of a $2.0 million clinical milestone from SB related to expanded development of Bexxar. Revenues from unconsolidated joint business represents our share of the pre-tax Bexxar operating losses generated from our joint business arrangement with SB to co-promote Bexxar and the reimbursement from SB of its share of our Bexxar-related manufacturing development expenses. Revenues from unconsolidated joint business in the three months ended September 30, 2000 was $1.2 million compared to $4.1 million for the same

period in 1999. For the nine months ended September 30, 2000, revenues from unconsolidated joint business were $6.9 million compared to $5.0 million for the same period in 1999. Such revenues were partially offset by co-promote pre-tax operating losses. The decrease for the quarter ended September 30, 2000 was due to a decrease in manufacturing development activities as we approach the anticipated launch of Bexxar. The increase for the nine months ended September 30, 2000 was due to the recognition in the first quarter of fiscal 2000 of a final payment of approximately $3.0 million related to 1999 manufacturing development activities. Revenue in future periods will depend on the achievement of contract milestones, the timing and scope of reimbursable development activities and commercial sales of Bexxar.

*Operating Costs and Expenses

Research and development expenses were $13.7 million for the three-month period ended September 30, 2000 compared to $12.4 million for the same period in 1999. For the nine months ended September 30, 2000, research and development expenses were $38.7 million compared to $33.4 million for the same period in 1999. The increase in research and development expenses for both periods in 2000 was primarily due to ongoing Bexxar-related clinical development activities, manufacturing activities in anticipation of potential product launch, and activities related to the acquisition of rights to certain technologies in support of our ongoing research. We expect our research and development expenses to grow during the remainder of 2000, reflecting anticipated increased costs related to additions to staffing, preclinical studies, clinical trials and manufacturing.

Selling, general and administrative expenses were $4.6 million for the quarter ended September 30, 2000, compared to $4.1 million for the same period in 1999. For the nine months ended September 30, 2000, selling, general and administrative expenses were $12.5 million compared to $11.5 million for the same period in 1999. The increase for the three- and nine-month periods was primarily due to expenses incurred to support our facilities and staffing expansion, sales and marketing efforts, increased pre-commercialization activities, increased corporate development activities and related legal and patent activities. We expect our selling, general and administrative expenses to continue to increase during the remainder of 2000 in continued support of these activities.

*Interest Income and Other, Net

Interest income and other, net was $821,000 for the quarter ended September 30, 2000, compared to $1.1 million for the same period in 1999. For the nine months ended September 30, 2000, interest income and other, net was $2.3 million compared to $3.8 million for the same period in 1999. These decreases were due to lower average cash, cash equivalents and short-term investment balances. Interest expense is not material for any period presented.

LIQUIDITY AND CAPITAL RESOURCES

Since our inception through September 30, 2000, we have financed our operations primarily through private placements and public offerings of equity securities totaling $215.6 million, including $33.6 million received in August 2000 pursuant to the sale of 1,655,000 shares of newly issued, unregistered common stock at a price of $21.625 per share. Cash, cash equivalents and short-term investments totaled $82.7 million at September 30, 2000. Our agreement with SB provides for the sharing of certain costs related to clinical and manufacturing development activities as well as a $15.0 million credit line, all of which was available at September 30, 2000. In October 2000, we borrowed all $15 million available under the credit line. In 1999, we obtained a credit line with GE Capital Leasing for $1.4 million relating to capital equipment leasing. Total available under this leasing credit line at the end of September 30, 2000 is $313,000.

The negative cash flow from operations results primarily from our net operating losses and is expected to continue and to accelerate in future periods. We expect to incur substantial and increasing research and development expenses, including expenses related to additions to personnel, preclinical studies, clinical trials, and manufacturing. In addition, we expect to incur increasing selling, general and administrative expenses in support of our commercialization efforts. We may need to raise substantial additional capital to fund our operations. We may seek such additional funding through public or private equity or debt financing from time to time, as market conditions permit. There can be no assurance that additional financing will be available on acceptable terms, if at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, product candidates or products that we would otherwise seek to develop or commercialize.

Net cash used in operations was $34.9 million for the nine months ended September 30, 2000, compared to $41.0 million for the same period in 1999. This $6.1 million decrease was primarily the result of increases in accounts payable and accrued liabilities,

partially offset by an increase in our net loss and prepaid and other current assets. Included in prepaid expenses and other current assets is approximately $5.5 million of monoclonal antibody purchased from one of our third-party manufacturers in the second quarter. The antibody will be used in our continued clinical research and development of Bexxar(TM) as well as potential future commercial use, pending Bexxar(TM) approval. Net cash provided by investing activities was $21.1 million for the nine months ended September 30, 2000 compared to net cash used in investing activities of $27.3 million for the same period in 1999. In the 2000 period, maturities of short-term investments exceeded purchases of such investments by $22.4 million. In the 1999 period, purchases of short-term investments exceeded maturities and sales by $16.0 million. Also in the 1999 period, we expended $10.8 million more in purchases of property and equipment than we did in 2000. The 1999 expenditures related primarily to our facilities expansion. Net cash provided by financing activities was $36.4 million for the nine months ended September 30, 2000 compared to $5.6 million for the same period in 1999. The increase was primarily due to the net proceeds from our August 2000 private placement of $33.6 million of common stock, partially offset by payments in equipment financing obligations.

We expect that our existing capital resources, including the net proceeds of our public offerings and interest thereon, will be adequate to satisfy the requirements of our current and planned operations through 2001. Our future capital requirements will depend on a number of factors, including: the scope and results of preclinical studies and clinical trials; continued progress of our research and development of potential products; the cost, timing and outcome of regulatory approvals; the expenses of establishing a sales and marketing force; the timing and cost of establishment or procurement of requisite production, radiolabeling and other capacities; the cost involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims; the need to acquire licenses to new technology; the status of competitive products; the availability of other financing and the ability to achieve profitability.

BUSINESS RISKS

Except for the historical information contained herein, the matters discussed in this filing are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of Bexxar or our other product candidates and other risks, including those detailed in our other filings with the Securities and Exchange Commission. In particular, see "Risk Factors," referenced in our Registration Statement on Form S-3 filed on August 30, 2000 and our Annual Report on Form 10-K for the year ended December 31, 1999, filed on March 27, 2000.




...viel Spaß damit

RR

[rainrain]

..die Reise geht doch noch weiter,
aktuell: 43,75$ +1$

Hier nochmal ein aktuelles Firmenprofil, für alle, die sich
einem künftigen Star befassen möchten:

Management`s Discussions: 10-Q, COULTER PHARMACEUTICALS INC
THURSDAY, NOVEMBER 02, 2000 1:45 PM
- Edgar Online

Company Name: COULTER PHARMACEUTICALS INC
(SYMBOL:CLTR)

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. Actual results may differ significantly from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and in our Registration Statement on Form S-3 filed on August 30, 2000 as well as in our Annual Report on Form 10-K for the year ended December 31, 1999, filed on March 27, 2000.

OVERVIEW

We are engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. We are currently developing a family of potential therapeutics based upon two drug discovery programs; therapeutic antibodies and targeted oncologies. Within these broad drug discovery programs, we are currently concentrating on several distinct platform technologies; therapeutic antibodies consisting of both conjugated and unconjugated antibody technology, and targeted oncologics based on tumor activated pro-drug ("TAP") technology and tumor specific targeting ("TST") technology. We are also developing a portfolio of proprietary ultra potent compounds which we believe will be suitable payloads for both our TAP and TST platforms. Ultra potent compounds generally are at least 1,000 times more potent than standard chemotherapeutic agents and are active against resistant tumor cells. In October 2000, we announced our intention to merge with Corixa Corporation, a research and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system.

Our most advanced product candidate, Bexxar(TM) (tositumomab, iodine I 131 tositumomab) consists of a monoclonal antibody conjugated with a radioisotope. We intend to seek initial approval of Bexxar for the treatment of low-grade and transformed low-grade non-Hodgkin`s lymphoma ("NHL") in patients who have relapsed after, or are refractory to, chemotherapy. We intend to seek expedited Biologics License Application ("BLA") review and marketing approval for Bexxar, while simultaneously pursuing clinical trials to expand the potential use of Bexxar to other indications. Bexxar is based upon the antibody therapeutics program which originated at Coulter Corporation. In September 2000, we announced the submission of a BLA for Bexxar to the Food and Drug Administration ("FDA") and in October 2000, we announced that Bexxar had been granted Priority Review Status by the FDA. In 1995, Coulter Pharmaceutical was incorporated and acquired worldwide rights to Bexxar and related intellectual property, know-how and other assets from Coulter Corporation. In 1997, Beckman Instruments, Inc. acquired Coulter Corporation, and is now known as Beckman Coulter. In December 1998, we announced a joint collaboration agreement with SmithKline Beecham Corporation ("SB") granting SB joint marketing rights to Bexxar in the United States and exclusive commercial rights internationally, except Japan. In April 2000, we announced that we reacquired rights outside the U.S. for the development and commercialization of Bexxar effective June 30, 2000.

To date, we have devoted substantially all of our resources to research and development programs, as well as selling, general and administrative activities needed to support product development and potential product sales. No revenues have been generated from product sales, and product revenues resulting from our research and development efforts, if any, will not occur until commercial availability of such product. We have a limited history of operations and have experienced significant operating losses to date. We may continue to incur significant additional operating losses in future periods and expect cumulative losses to increase substantially due to expanded research and development efforts, preclinical studies and clinical trials and development of manufacturing, marketing and sales capabilities, if anticipated product sales revenues do not offset these costs. We expect that losses will fluctuate from quarter to quarter and that such fluctuations may be substantial. There can be no assurance that we will successfully develop, manufacture and commercialize our products or ever achieve or sustain product revenues or profitability. As of September 30, 2000, our accumulated deficit was approximately $137.2 million.

RESULTS OF OPERATIONS

*Revenues

Corporate partner revenues of $2.0 million for the nine-month period ended September 30, 2000 resulted from the recognition of a $2.0 million clinical milestone from SB related to expanded development of Bexxar. Revenues from unconsolidated joint business represents our share of the pre-tax Bexxar operating losses generated from our joint business arrangement with SB to co-promote Bexxar and the reimbursement from SB of its share of our Bexxar-related manufacturing development expenses. Revenues from unconsolidated joint business in the three months ended September 30, 2000 was $1.2 million compared to $4.1 million for the same

period in 1999. For the nine months ended September 30, 2000, revenues from unconsolidated joint business were $6.9 million compared to $5.0 million for the same period in 1999. Such revenues were partially offset by co-promote pre-tax operating losses. The decrease for the quarter ended September 30, 2000 was due to a decrease in manufacturing development activities as we approach the anticipated launch of Bexxar. The increase for the nine months ended September 30, 2000 was due to the recognition in the first quarter of fiscal 2000 of a final payment of approximately $3.0 million related to 1999 manufacturing development activities. Revenue in future periods will depend on the achievement of contract milestones, the timing and scope of reimbursable development activities and commercial sales of Bexxar.

*Operating Costs and Expenses

Research and development expenses were $13.7 million for the three-month period ended September 30, 2000 compared to $12.4 million for the same period in 1999. For the nine months ended September 30, 2000, research and development expenses were $38.7 million compared to $33.4 million for the same period in 1999. The increase in research and development expenses for both periods in 2000 was primarily due to ongoing Bexxar-related clinical development activities, manufacturing activities in anticipation of potential product launch, and activities related to the acquisition of rights to certain technologies in support of our ongoing research. We expect our research and development expenses to grow during the remainder of 2000, reflecting anticipated increased costs related to additions to staffing, preclinical studies, clinical trials and manufacturing.

Selling, general and administrative expenses were $4.6 million for the quarter ended September 30, 2000, compared to $4.1 million for the same period in 1999. For the nine months ended September 30, 2000, selling, general and administrative expenses were $12.5 million compared to $11.5 million for the same period in 1999. The increase for the three- and nine-month periods was primarily due to expenses incurred to support our facilities and staffing expansion, sales and marketing efforts, increased pre-commercialization activities, increased corporate development activities and related legal and patent activities. We expect our selling, general and administrative expenses to continue to increase during the remainder of 2000 in continued support of these activities.

*Interest Income and Other, Net

Interest income and other, net was $821,000 for the quarter ended September 30, 2000, compared to $1.1 million for the same period in 1999. For the nine months ended September 30, 2000, interest income and other, net was $2.3 million compared to $3.8 million for the same period in 1999. These decreases were due to lower average cash, cash equivalents and short-term investment balances. Interest expense is not material for any period presented.

LIQUIDITY AND CAPITAL RESOURCES

Since our inception through September 30, 2000, we have financed our operations primarily through private placements and public offerings of equity securities totaling $215.6 million, including $33.6 million received in August 2000 pursuant to the sale of 1,655,000 shares of newly issued, unregistered common stock at a price of $21.625 per share. Cash, cash equivalents and short-term investments totaled $82.7 million at September 30, 2000. Our agreement with SB provides for the sharing of certain costs related to clinical and manufacturing development activities as well as a $15.0 million credit line, all of which was available at September 30, 2000. In October 2000, we borrowed all $15 million available under the credit line. In 1999, we obtained a credit line with GE Capital Leasing for $1.4 million relating to capital equipment leasing. Total available under this leasing credit line at the end of September 30, 2000 is $313,000.

The negative cash flow from operations results primarily from our net operating losses and is expected to continue and to accelerate in future periods. We expect to incur substantial and increasing research and development expenses, including expenses related to additions to personnel, preclinical studies, clinical trials, and manufacturing. In addition, we expect to incur increasing selling, general and administrative expenses in support of our commercialization efforts. We may need to raise substantial additional capital to fund our operations. We may seek such additional funding through public or private equity or debt financing from time to time, as market conditions permit. There can be no assurance that additional financing will be available on acceptable terms, if at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, product candidates or products that we would otherwise seek to develop or commercialize.

Net cash used in operations was $34.9 million for the nine months ended September 30, 2000, compared to $41.0 million for the same period in 1999. This $6.1 million decrease was primarily the result of increases in accounts payable and accrued liabilities,

partially offset by an increase in our net loss and prepaid and other current assets. Included in prepaid expenses and other current assets is approximately $5.5 million of monoclonal antibody purchased from one of our third-party manufacturers in the second quarter. The antibody will be used in our continued clinical research and development of Bexxar(TM) as well as potential future commercial use, pending Bexxar(TM) approval. Net cash provided by investing activities was $21.1 million for the nine months ended September 30, 2000 compared to net cash used in investing activities of $27.3 million for the same period in 1999. In the 2000 period, maturities of short-term investments exceeded purchases of such investments by $22.4 million. In the 1999 period, purchases of short-term investments exceeded maturities and sales by $16.0 million. Also in the 1999 period, we expended $10.8 million more in purchases of property and equipment than we did in 2000. The 1999 expenditures related primarily to our facilities expansion. Net cash provided by financing activities was $36.4 million for the nine months ended September 30, 2000 compared to $5.6 million for the same period in 1999. The increase was primarily due to the net proceeds from our August 2000 private placement of $33.6 million of common stock, partially offset by payments in equipment financing obligations.

We expect that our existing capital resources, including the net proceeds of our public offerings and interest thereon, will be adequate to satisfy the requirements of our current and planned operations through 2001. Our future capital requirements will depend on a number of factors, including: the scope and results of preclinical studies and clinical trials; continued progress of our research and development of potential products; the cost, timing and outcome of regulatory approvals; the expenses of establishing a sales and marketing force; the timing and cost of establishment or procurement of requisite production, radiolabeling and other capacities; the cost involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims; the need to acquire licenses to new technology; the status of competitive products; the availability of other financing and the ability to achieve profitability.

BUSINESS RISKS

Except for the historical information contained herein, the matters discussed in this filing are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of Bexxar or our other product candidates and other risks, including those detailed in our other filings with the Securities and Exchange Commission. In particular, see "Risk Factors," referenced in our Registration Statement on Form S-3 filed on August 30, 2000 and our Annual Report on Form 10-K for the year ended December 31, 1999, filed on March 27, 2000.




...viel Spaß damit

RR

[toller]

hey rain rain!!!!
es hat funktioniert!!!! Bexxar ist akzeptiert!!!

Die letzten tage waren nicht so toll, wahrscheinlich wussten die amis, dass was im busch war und hatten angst vor einer erneuten Ablehnung des Antrages bei der FDA. wahrscheinlich waren auch einfach einige dabei die dachten, dass die gewinne der letzten wochen mal mitgenommen werden könnten. however, ich bin noch drin und gebe meine ab für 130euro ;-)))

vieleicht kannst Du jetzt meine skepsis verstehen, die ich hatte als der verkauf an Corixa bekannt wurde. denn leider steht der Exchange ja schon fest im verhältnis 1:1,003 d.h. wir sind totz der Acceptance des Antrags immer noch an den dämlichen Kurs von Corixa gebunden....


viele Grüße.

Coulter Pharmaceutical and SmithKline Beecham Announce Acceptance of License Application for Bexxar
Coulter to Receive $5 Million Equity Investment From SmithKline Beecham
SOUTH SAN FRANCISCO, Calif. & PHILADELPHIA--(BW HealthWire)--Nov. 14, 2000--Coulter Pharmaceutical, Inc. (Nasdaq:CLTR - news) and SmithKline Beecham (NYSE:SBH - news) today announced that the Biologics License Application (BLA) for Bexxar(TM) (tositumomab, iodine I 131 tositumomab) has been accepted for filing by the U.S. Food and Drug Administration. The companies are seeking marketing approval of Bexxar for the treatment of relapsed or refractory, low-grade or transformed low-grade B-cell non-Hodgkin`s lymphoma (NHL). If approved, Bexxar would be the first radioimmunotherapy to be made commercially available.

``We are delighted by the acceptance of the Bexxar BLA,`` said Michael F. Bigham, president and chief executive officer of Coulter Pharmaceutical. ``The acceptance represents an important milestone in the approval process for Bexxar. We look forward to working with the FDA and our partner SmithKline Beecham to make this product available to the patients who suffer from this devastating disease.``

The BLA for Bexxar was received by the FDA on September 15, 2000, and the application has been assigned six-month priority review status. Upon acceptance of the BLA, Coulter Pharmaceutical will receive a $5 million equity investment from partner SmithKline Beecham.

``The data included in the BLA underscore the potentially important role of Bexxar in treating and managing patients with these forms of non-Hodgkin`s lymphoma,`` commented Kevin Lokay, vice president and director of Oncology for SmithKline Beecham.

Bexxar is the only radioimmunotherapy that combines the targeting ability of a monoclonal antibody and the therapeutic power of radiation, with the precision of patient-specific dosing. The radiolabeled monoclonal antibody attaches to a target marker found on NHL affected cells thereby eliciting an immune response and delivers a dose of iodine 131 radiation to tumor cells. Bexxar is the first NHL therapy that is precisely dosed based on individual drug clearance rates.

``We are pleased that Bexxar is on track for review by the FDA,`` said Ilene Penn-Miller, executive director of the Cure for Lymphoma Foundation. ``Non-Hodgkin`s lymphoma has historically been a difficult form of cancer to treat and there is a definite need for cutting edge therapies that could improve patient prognosis and possibly improve the likelihood of long-term survival.``

Non-Hodgkin`s lymphoma is a form of cancer that affects the blood and lymph tissues. NHL currently is the sixth leading cause of death among cancers in the United States and has the second fastest growing mortality rate. According to statistics from the National Cancer Institute, approximately 300,000 people are afflicted with NHL in the United States alone. Of the total, the company estimates that approximately 140,000 people have low-grade or transformed low-grade disease.

Coulter Pharmaceutical, Inc. is engaged in the development of novel drugs and therapies for the treatment of cancer and autoimmune diseases. The company currently is developing a family of cancer therapeutics based upon two drug development programs: therapeutic antibodies and targeted oncologics. The company`s most advanced product candidate is Bexxar(TM), a monoclonal antibody conjugated to a radioisotope. Initial efforts in the targeted oncologics program are focused on the development of a tumor-activated peptide pro-drug version of doxorubicin to potentially treat certain solid tumor cancers. The company`s therapeutic antibody program includes an antibody-based approach to block the Type I interferon receptor for the treatment of autoimmune diseases and transplant rejection. On October 16, 2000, Coulter Pharmaceutical, Inc. announced its intention to merge with Corixa, a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. For more company information, visit Coulter Pharmaceutical`s web site at www.coulterpharm.com and Corixa`s web site at www.corixa.com.

SmithKline Beecham -- one of the world`s leading healthcare companies discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products. For company information, visit SmithKline Beecham on the World Wide Web at http://www.sb.com.

SmithKline Beecham Oncology is committed to the research, development, manufacturing and marketing of therapeutic and supportive care products in oncology. Currently, SB Oncology markets Hycamtin (topotecan hydrochloride), Kytril (granisetron hydrochloride) and Compazine prochlorperazine), and has novel agents in development.

Except for the historical information contained herein, the matters discussed in this news release include forward-looking statements relating to Coulter Pharmaceutical, Inc. that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of Bexxar(TM) or the company`s other product candidates and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC). In particular, see ``Risk Factors`` in the company`s Registration Statement on Form S-3 filed August 30, 2000, and Annual Report on Form 10-K for the year ended December 31, 1999.

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, SmithKline Beecham cautions investors that any forward-looking statements or projections made by the company, including those made in this news release, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the company`s operations are discussed in Exhibit 99 to the company`s Annual Report on Form 20-F for 1998, filed with the U.S. Securities and Exchange Commission.


--------------------------------------------------------------------------------
Contact:

Coulter Pharmaceutical, Inc.
Sylvia Wheeler, 650/553-2000
or
SmithKline Beecham

[rainrain]

@toller

jippieeeeee!!!

das war der startschuß... neubewertung, wird corixa mitziehen.

130€? ...aber mindestens

schöne Grüße

rainrain

[toller]

Hi Rainrain,

coulter hat ja leider mächtig punkte gelassen seit dieser beschissenen Bilanz von Corixa. Naja, das Börsenumfeld in USA war ja auch nicht gearde rosig.

bleibt nur zu hoffen, dass jetzt alle angsthasen raus sind, die befürchten, Bexxar erhält keine Zulassung als Medikament. ich bleib mal noch dabei, schon allein um die 50Euro zusehen....und dann natürlich die 130 ;-))

bis denn und grüße
Toller

[rainrain]

hi toller,

lange nichts mehr gehört, ist auch nichts schönes passiert.
Der Kurs ist mächtig zusammengebrochen, und ich frage mich immer noch, warum.... bist du noch dabei?
Hier noch die letzten Meldungen, der Kurs ist heute auch vom Handel ausgesetzt:

Corixa and Coulter Complete Merger to Form Comprehensive Immunotherapy Company
FRIDAY, DECEMBER 22, 2000 6:18 PM
- BusinessWire

SEATTLE, Dec 22, 2000 (BW:CRXA), a research- and development-based biotechnology company, today announced the completion of the merger between Corixa and San Francisco-based Coulter Pharmaceutical, Inc. following stockholder votes at both company meetings.

The merger combines Corixa`s antigen discovery and immunotherapeutic product development expertise with Coulter`s therapeutic antibodies and targeted oncologics platforms to develop therapies for the treatment or prevention of autoimmune diseases, cancer and infectious diseases. The merged company, which will operate under the Corixa Corporation name, creates a comprehensive, turnkey immunotherapy company focused on discovering antigens, developing them into products and taking those products to market.

The combined Corixa and Coulter product portfolio includes two late stage products for which Biologic License Applications (BLAs) have been filed or are in preparation: Bexxar(TM) (tositumomab, iodine I 131 tositumomab) and Melacine, respectively. Corixa now has a combined product pipeline that includes 16 programs in clinical development and 22 preclinical programs, as well as 16 corporate partnerships. The BLA for Bexxar, a radioimmunotherapy comprised of a monoclonal antibody conjugated to a radioisotope, was received by the U.S. Food and Drug Administration (FDA) on September 15, 2000, and subsequently assigned six-month priority review status. On November 14, 2000, the FDA accepted the BLA for review. Also part of the combined pipeline of potential products are Melacine(R), Corixa`s therapeutic cancer vaccine; MPL(R), Corixa`s widely partnered vaccine adjuvant that is sold on a named-patient basis in Germany for the treatment of allergies; and PVAC(TM), Corixa`s clinical stage immunotherapy for psoriasis.

On October 16, 2000, Corixa announced the signing of a definitive agreement to acquire all outstanding shares of Coulter in a stock-for-stock merger. Coulter shareholders will receive 1.003 shares of Corixa common stock for each share of Coulter common stock currently outstanding. Based on the closing price of Corixa common stock and the number of Coulter shares outstanding, the transaction was valued at approximately $570 million. The transaction is intended to qualify as a tax-free reorganization and will be accounted for as a purchase.

"Today`s announcement represents a significant step for Corixa in its pursuit of becoming the leading immunotherapy company," said Steven Gillis, chairman and chief executive officer of Corixa. "Coulter`s expertise in therapeutic antibody research, as is evident in the successful clinical development of Bexxar, further strengthens Corixa`s research capabilities, broadens our product pipeline and enables us to bring more immunotherapy products to market faster than ever before. We are pleased that both companies` stockholders endorsed the transaction and we look forward to completing the integration and to continuing our progress in the laboratory, clinic and the marketplace."

Corixa plans to integrate Corixa`s existing Redwood City, Calif. facility with Coulter`s South San Francisco operations. The combined company now has approximately 525 employees, located in Seattle, Hamilton, Mont., and South San Francisco. On November 27, Corixa also confirmed in a press release the composition of its board of directors and management team (see press release entitled "Corixa and Coulter Provide Program and Operations Update on Merger" in the news and events section of Corixa`s Web site at www.corixa.com).

About Corixa
Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar(TM), a monoclonal antibody conjugated to a radioisotope.

The company partners with numerous developers and marketers of pharmaceuticals and diagnostics, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. and South San Francisco, Calif. For more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at 877-4CORIXA or 877/426-7492.

Forward-Looking Statements
Except for the historical information presented, certain matters discussed in this press release are forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. They are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect Corixa`s actual results include, but are not limited to the "Factors Affecting Our Operating Results, Our Business and Our Stock Price," described in our Quarterly Report on Form 10-Q/A filed on November 7, 2000 and our Registration Statement on Form S-4/A filed on November 17, 2000, copies of which are available on our Web site, www.corixa.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

CONTACT: Corixa Corporation
Investor Relations
Jim DeNike, 206/754-5716
[e-mail]
or
FitzGerald Communications Inc.
Press Relations
Jennifer Reinhard, 415/986-9500
[e-mail]

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.


RR

[rainrain]

hi toller,

bist du noch dabei? Der CORIXA Chart sieht auch nicht schlecht aus, und das Unternehmen macht mir einen sehr soliden Eindruck.




Coulter ist geschluckt, es lebe CRXA!!

RR

[toller]

hi Rainrain und romeo,

ja bin noch dabei, aber so ganz schlau wird man aus dem verlauf von CRXA nicht. die ganze situation wirkt wie paralysiert durch den noch ausstehenden Zulassungsbescheid von der FDA für BEXXAR. bis da die ersten gerüchte auftauchen, wird sich nicht viel tun.


Hier noch ein Rating von Prudential Sec. vom 11.januar01

Corixa Corp STRONG BUY
CRXA: CORIXA NOW HAS 5 PRODUCTS IN PHASE III OR BETTER
CRXA | $24.00 | NASD

Corixa has initiated a pivotal hepatitis B trial with a novel adjuvant called RC-529. Trial is in combination with AgB, an approved hepatitis B vaccine. Corixa now has 5 phase III or registration phase drug candidates.


RC-529 is a Ribi-derived adjuvant that is commonly referred to as a synthetic version of lead adjuvant MPL. Corixa owns all WW rights to RC-529.


****
gut finde ich, dass die nun 5 produkte in Pase III oder höher haben.
Nur, wie gesagt, ändern wird sich IMO nichts grossartig, bis die Bexxar zulassung oder ablehnung kommt.

grüsse
toller

[rainrain]

Corixa Receives U.S. Patent for Chemokine Receptor Polypeptide for Inhibiting Inflammatory Responses Associated With Autoimmune Disease
MONDAY, JANUARY 29, 2001 8:08 AM
- BusinessWire

SEATTLE, Jan 29, 2001 (BW:CRXA), a research- and development-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a patent covering certain compositions and methods for inducing an immune response using chemokine receptor peptides.

The novel compositions and methods claimed in U.S. Patent Number 6,171,590 cover the inhibition of inflammatory responses associated with autoimmune diseases, such as multiple sclerosis, by vaccinating with specific chemokine receptor protein subunits.

Chemokines are a family of proteins that act as chemical messengers in the immune system to promote the recruitment and activation of leukocytes (cells that help the body fight disease) and lymphocytes. Chemokines regulate the trafficking of tissue reactive T cells by interacting with specific chemokine receptors expressed by these cells. By vaccinating against portions of the receptor, experiments in animal models have demonstrated that immune responses can be directed toward inhibiting the interaction of a given chemokine with its receptor, thereby reducing recruitment of auto-immune T-cells and inhibiting the disease process.

The patented method of inducing an immune response against a chemokine receptor molecule involves administering to a patient an adjuvant and an immunogenic chemokine receptor polypeptide from an extracellular region of a CXCR3 chemokine receptor molecule.

"The inhibition of chemokine receptor signaling via vaccination represents another novel means of developing a new class of potential therapies for the management of multiple autoimmune diseases," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "While a variety of biological chemokine antagonists are being tested clinically, most of these molecules are passively administered antibodies that need to be given continually to mediate a biologically beneficial effect in autoimmune disease. Vaccination to promote a patient`s own antibody and cell mediated immune responses has the potential of providing more effective and long-lasting therapeutic benefit."

About Corixa

Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar(TM), a monoclonal antibody conjugated to a radioisotope.

The company partners with numerous developers and marketers of pharmaceuticals and diagnostics, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. and South San Francisco, Calif. For more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at 877/4CORIXA or 877/426-7492.

Forward-Looking Statements

Except for the historical information presented, certain matters discussed in this press release are forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. They are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect Corixa`s actual results include, but are not limited to failure of the patented technology to prove safe or efficacious in patients and the "Factors Affecting Our Operating Results, Our Business and Our Stock Price," described in our Quarterly Report on Form 10-Q/A filed on November 7, 2000 and our Registration Statement on Form S-4/A filed on November 17, 2000, copies of which are available on our Web site, http://www.corixa.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

CONTACT:

Corixa Corporation
Jim DeNike, 206/754-5716 (Investor Relations)
[e-mail]
or
FitzGerald Communications Inc.
Jen Reinhard, 415/986-9500 (Media Relations)
[e-mail]